# Hightide

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hightide

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.hightidetx.com
- Total disclosed funding: $107M
- Latest round: Series C (Jan 5, 2023)
- Investors on record: 14

## About

Established in 2011 and based in Shenzhen, China, Hightide operates as a biopharmaceutical research and development company that focuses on the R&D of new drugs for metabolic and digestive diseases. It has R&D centres in the USA and China. Dr. Liping Liu, the company's founder, received a doctoral degree in Polymer Chemistry and Physics from Nankai University, once worked in U.S. biotech companies, including Associate Director of Antigen Discovery of CTL ImmunoTherapies Corporation, MannKind Corporation, American Type Culture Collection, Head of Global R&D of Stealth Peptide Inc., and own10 IND submissions, and 100 patents. As of January 2023, HTD1801 has entered into a clinical 2 study. HTD1801The U.S. Food and Drug Administration (FDA) granted fast-track designation to HTD1801 for NASH and PSC. And HTD1801 was included in the National Major New Drug Innovation Program in China. In December 2023, it raised a pre-IPO funding for CNY 100 million.

The company focuses on therapeutic discovery, development and commercialization of multifunctional and multi-targeted therapies for metabolic and digestive diseases. It provides the molecular drug, HTD1801, for the treatment of type 2 diabetes (T2DM), nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC).

The company has 2022 revenue of CNY 20.581 million and net income of CNY -190.237 million.

The company will use the Pre-IPO funding for its core product, HTD1801, as well as for the continued clinical development of HTD1804 for the treatment of obesity, upgrades and enhancements to the development of FUSIONTXTM, and for working capital.

## Funding rounds

- Series C, Jan 5, 2023, $107M — China Development Bank Capital, Yuexiu Industrial Investment Funds Management, Yuthai Investment
- Series B, Dec 8, 2020 — Cowin Capital, CITIC Securities, Winzac Capital Management, BOCG, Tigermed, Greater Bay Area Homeland Investments Ltd., Jiatai Fund, Chengdu Hunt Zest Investment Management, Borui Capital
- Angel, Jul 27, 2016 — TF Capital, Nanfang Haichuang Fund Management (Shenzhen)

## Investors

- TF Capital — Angel
- Nanfang Haichuang Fund Management (Shenzhen) — Angel
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series B
- CITIC Securities — Series B
- Winzac Capital Management (https://capitalatlas.ai/funds/winzac-capital-management) — Series B
- BOCG (https://capitalatlas.ai/funds/bocg) — Series B
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series B
- Greater Bay Area Homeland Investments Ltd. — Series B
- Jiatai Fund — Series B
- Chengdu Hunt Zest Investment Management — Series B
- Borui Capital — Series B
- China Development Bank Capital — Series C
- Yuexiu Industrial Investment Funds Management (https://capitalatlas.ai/funds/yuexiu-industrial-investment-funds-management) — Series C
- Yuthai Investment — Series C